World-renowned oncologist Dr. Baofa Yu MD has opened 3 hospitals within 3 different cities in China, including Beijing, that specialize in treating solid tumors. He has developed a new intra-tumor treatment called UMIPIC - Ultra Minimum Incision Personalized Intra-Tumoral ChemoImmunology Therapy, which has been used to treat over 50000 patients in 21 years, with superior advantages and results as compared to other treatment therapies.


Dr. Yu attended the San Diego Medical School of UCSD to continue his postdoctoral study in 1990 after graduating from Chinese medical college and gaining four years of working experience in hospitals in China. He performed drug delivery research for cancer therapy in the Cancer Center of UCSD for two years. Following that, he conducted research involving the molecular biology of cancer in the Salk Institute for Biological Studies for two years; then he worked in a clinical department for four years, specializing in oncology and as an assistant professor of UCSD. He has now published more than 15 papers in a variety of scientific journals.

American SALK medical research group photo

Dr. Yu's UMIPIC therapy is a new intra-tumor therapy involving an injection to the tumor directly through a specialized needle, for which he applied and gained a patent for in the US, as well as patents in both China and Australia. 
He returned to China in 1998 to set up his first hospital in his home town, Dongping, where he achieved great success with his unique treatment. Thereafter, he opened two more hospitals in the cities of Jinan and Beijing. With the superior advantages and results of his UMIPIC Therapy, patients have come from all over the world including China, US, Canada, and France. Dr. Yu has also been invited to give speeches and lectures of his new therapy in several conferences and seminars in various countries. 

The patent certificate
Dr. Yu’s three hospitals have acquired over 500 employees including about 50 doctors giving treatments to hundreds of patients every day. Having accumulated years of clinical research and experience, we are still evolving and improving the therapy by adding new agents in the medication based on the patient’s specific situation. 

Group photo of all staff